With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in important areas within the pharma industry. Investors could see the two ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...